Trexquant Investment LP Sells 10,611 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Trexquant Investment LP lowered its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 6.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 156,656 shares of the biopharmaceutical company's stock after selling 10,611 shares during the period. Trexquant Investment LP owned about 0.17% of Ultragenyx Pharmaceutical worth $6,591,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in RARE. Smartleaf Asset Management LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 259.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 493 shares during the period. Human Investing LLC acquired a new stake in Ultragenyx Pharmaceutical during the 4th quarter valued at $42,000. Van ECK Associates Corp lifted its holdings in shares of Ultragenyx Pharmaceutical by 18.4% in the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock valued at $74,000 after purchasing an additional 273 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Ultragenyx Pharmaceutical in the third quarter worth $83,000. Finally, Nomura Asset Management Co. Ltd. purchased a new position in shares of Ultragenyx Pharmaceutical during the third quarter valued at $93,000. 97.67% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical Trading Down 6.4 %

RARE traded down $2.16 on Thursday, hitting $31.75. 265,839 shares of the stock traded hands, compared to its average volume of 842,977. The business has a fifty day moving average price of $39.78 and a two-hundred day moving average price of $45.21. The firm has a market capitalization of $2.98 billion, a PE ratio of -5.00 and a beta of 0.61. Ultragenyx Pharmaceutical Inc. has a 52 week low of $29.59 and a 52 week high of $60.37.

Remove Ads

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing analysts' consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The firm had revenue of $164.88 million during the quarter, compared to analyst estimates of $163.23 million. On average, equities research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Insider Transactions at Ultragenyx Pharmaceutical

In related news, insider John Richard Pinion sold 14,439 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $607,881.90. Following the completion of the transaction, the insider now owns 107,766 shares in the company, valued at $4,536,948.60. This trade represents a 11.82 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Howard Horn sold 1,785 shares of the business's stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $40.40, for a total value of $72,114.00. Following the completion of the sale, the chief financial officer now directly owns 106,169 shares in the company, valued at approximately $4,289,227.60. This represents a 1.65 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 124,643 shares of company stock valued at $5,256,268. Company insiders own 5.80% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $118.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th. Wells Fargo & Company boosted their price objective on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an "overweight" rating in a research report on Friday, December 20th. Canaccord Genuity Group increased their target price on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a "buy" rating in a research report on Tuesday, February 18th. Wedbush restated a "neutral" rating and set a $48.00 price target (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. Finally, HC Wainwright restated a "buy" rating and set a $95.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, February 14th. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $92.79.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.